Immune Thrombocytopenia
Conditions
Keywords
Immune Thrombocytopenia (ITP), Thrombopoietin (TPO) agents, children, romiplostim and eltrombopag
Brief summary
This is a retrospective analysis of children (≤21years old) who received clinical treatment with either Romiplostim or Eltrombopag at 2 medical centers from 2009-2013. The children included in this study were from Weill Medical College of Cornell University, New York, New York and Children's Hospital Orange County, Orange, California
Interventions
None listed
Sponsors
Children's Hospital of Orange County
Weill Medical College of Cornell University
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Months to 21 Years
Healthy volunteers
No
Inclusion criteria
1\. All patients in this study had received prior treatments before the start of TPO treatment including corticosteroids, IVIG, IV anti-D, and/or Rituximab.
Exclusion criteria
1\. Children who do not have ITP
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet count greater than or = to 50,000 | on two consecutive weeks |
Secondary
| Measure | Time frame |
|---|---|
| An increase in platelets greater than or = to 20,000 over baseline. | On two consecutive weeks |
Other
| Measure | Time frame |
|---|---|
| Percentage of weeks with platelet counts greater than or = to 50,000 independent of rescue therapy. | For Rescue therapy is defined as receiving Intravenous Immunoglobulin (IVIG) increased dose steroids or platelet transfusions . When given this resulted in exclusion of platelet counts for 2 full weeks after indication of rescue therapy .. |
Countries
United States
Outcome results
None listed